- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02428894
Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation
July 14, 2017 updated by: University of Colorado, Denver
The purpose of this study is to characterize changes in the plasma proteome over time following left ventricular assist device (LVAD) implantation.
Study Overview
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Study participants will be recruited from the University of Colorado Hospital Advanced Heart Failure Program.
Description
Inclusion Criteria:
- Planned HeartMate II LVAD implantation
- Planned warfarin (goal INR, 2.0-3.0) and low-dose aspirin therapy post-LVAD placement
Exclusion Criteria:
- Prior history of mechanical circulatory support;
- Body weight < 110 lbs;
- Pre-existing hemolytic, bleeding, or immunologic disorders prior to LVAD implantation;
- Severe aortic stenosis;
- Renal failure requiring dialysis;
- Hepatic dysfunction resulting in severe coagulopathies;
- Recent serious infection;
- Current need for prolonged ventilatory support;
- Prior organ transplantation;
- Blood transfusion within 14 days of the first planned study blood draw;
- Concomitant immunosuppressant or chemotherapeutic agents;
- Pregnant women;
- Decisionally challenged or prisoners;
- Unwilling to provide written informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
LVAD recipients
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quantitative differences in plasma protein abundance
Time Frame: Days 7, 14, 30, 60, 90, and 180 post-LVAD implantation
|
Days 7, 14, 30, 60, 90, and 180 post-LVAD implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christina Aquilante, Pharm.D., University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
April 17, 2015
First Submitted That Met QC Criteria
April 23, 2015
First Posted (Estimate)
April 29, 2015
Study Record Updates
Last Update Posted (Actual)
July 17, 2017
Last Update Submitted That Met QC Criteria
July 14, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-1376
- 14GRNT20380495 (Other Grant/Funding Number: American Heart Association)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Dysfunction, Left
-
Ceric SàrlNot yet recruitingLeft Ventricular Dysfunction | Left Ventricular (LV) Systolic Dysfunction | Left Ventricular Cardiac Dysfunction | Left Ventricular Ejection Fraction | Tricuspid Insufficiency | Tricuspid Regurgitation (TR)
-
Mayo ClinicNot yet recruitingMenopause | Left Ventricular DysfunctionUnited States
-
Tri-Service General HospitalRecruitingLeft Ventricular (LV) Systolic DysfunctionTaiwan
-
Berlin Heart, IncUnknownSevere Isolated Left Ventricular Dysfunction | Severe Biventricular Dysfunction
-
Ataturk UniversityNot yet recruitingLeft Ventricular Dysfunction | Cardiopulmonary Bypass SurgeryTurkey (Türkiye)
-
Lawson Health Research InstituteMedtronicTerminatedHeart Failure, Left Ventricular DysfunctionCanada
-
Berlin Heals GmbHRecruitingSystolic Left Ventricular DysfunctionCroatia, Serbia, Bosnia and Herzegovina, North Macedonia
-
Berlin Heals GmbHCompletedSystolic Left Ventricular DysfunctionGermany, Serbia, Croatia, Switzerland, Spain, Bosnia and Herzegovina, Bulgaria, Czechia, Greece, North Macedonia, Poland
-
M.D. Anderson Cancer CenterCompletedHeart Failure | Cancer Treatment Induced Left Ventricular DysfunctionUnited States
-
AstraZenecaCompletedLeft Ventricle FunctionSweden
Clinical Trials on LVAD
-
University of FloridaCompletedHeart FailureUnited States
-
BrioHealth BVMeditrial SrLNot yet recruitingRefractory Heart Failure | Cardiovascular Diseases (CVD)
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of Texas; Carelon...Not yet recruitingHeart Failure With Reduced Ejection Fraction | LVAD | Pediatric HD, Stage IV
-
Baylor College of MedicinePatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; The... and other collaboratorsCompletedEnd-Stage Heart Failure | Bridge-to-Transplant LVAD Placement (BTT) | Destination Therapy LVAD Placement (DT) | Refusal of LVAD Placement (Decliners) | LVAD CaregiversUnited States
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart Failure, CongestiveUnited States
-
Help TherapeuticsNot yet recruitingHeart Failure | Heart Failure At NYHA Stage III or IVChina
-
University of Southern CaliforniaWithdrawn
-
STAVROS G DRAKOSAmerican Heart AssociationRecruiting
-
Terumo Heart Inc.TerminatedHeart FailureUnited States, Canada
-
Medtronic Cardiac Rhythm and Heart FailureCompletedChronic Heart FailureUnited States